Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP.

Molecular cell·2026
Same author

BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.

British journal of haematology·2026
Same author

Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.

Journal of hematology & oncology·2025
Same author

Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms.

Chemical science·2025
Same author

SEC61B regulates calcium flux and platelet hyperreactivity in diabetes.

The Journal of clinical investigation·2025
Same author

Ischaemic endothelial necroptosis induces haemolysis and COVID-19 angiopathy.

Nature·2025
Same journal

Why high scores do not mean application readiness for health AI.

Nature medicine·2026
Same journal

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.

Nature medicine·2026
Same journal

Biological aging might help to explain the rising risk of early-onset cancer.

Nature medicine·2026
Same journal

Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection.

Nature medicine·2026
Same journal

A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials.

Nature medicine·2026
Same journal

Blood-based circular RNAs for early diagnosis of Alzheimer's disease.

Nature medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 1, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

Boosting platelet production

Andrew Wei1, Shaun P Jackson

  • 1Australian Centre for Blood Diseases, Monash University, Alfred Medical Research and Education Precinct, 89 Commercial Road, Melbourne, Victoria 3004, Australia.

Nature Medicine
|September 9, 2008
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion
08:34

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Published on: February 24, 2021

Related Experiment Videos

Last Updated: Jul 1, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion
08:34

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Published on: February 24, 2021